So, the present study was designed to investigate the effects of the GLP1 analogue and SGLT2 inhibitor on DCM and diabetic CAN in T2DM and to clarify their underlying mechanisms. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.